Literature DB >> 3349462

Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.

M M Mareel1, G A Storme, C H Dragonetti, G K De Bruyne, B Hartley-Asp, J L Segers, M L Rabaey.   

Abstract

Estramustine (EM) is a conjugate of estradiol and nor-nitrogen mustard (nor-HN2), which is effective in the treatment of prostate cancer. We have compared the effect of EM with that of the known microtubule inhibitor vinblastine (VLB) on the following functions of malignant MO4 mouse cells and of DU-145 human prostate cancer cells in vitro: directional migration, invasion; and the organization and the assembly/disassembly equilibrium of microtubule complexes. The circular area covered by cells migrating from an aggregate explanted on a solid substrate was taken as an index of directional migration. Invasion was studied through confrontation of MO4 or DU-145 cells with fragments of embryonic chick heart in organ culture. Microtubules were investigated immunocytochemically and through immunodetection on protein blots. VLB and EM inhibited directional migration and invasion of MO4 and DU-145 cells in a dose-dependent manner; equimolar combinations of estradiol plus nor-nitrogen mustard did not mimic these effects. At anti-invasive concentrations VLB led to partial disassembly of microtubule complexes, whereas EM resulted in an abnormal pattern of microtubule complexes without alteration of the overall assembly/disassembly equilibrium. Combined treatment with VLB and EM resulted in an enhanced VLB effect, namely complete disassembly. In all tests DU-145 cells were more sensitive to both VLB and EM than were MO4 cells, and the effects were less reversible. The present experiments showed that EM shares an anti-invasive activity with other microtubule inhibitors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349462

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.

Authors:  D Panda; H P Miller; K Islam; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

2.  Estramustine phosphate reversibly inhibits an early stage during adenovirus replication.

Authors:  E Everitt; H Ekstrand; B Boberg; B Hartley-Asp
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 3.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

4.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly.

Authors:  T Usui; M Kondoh; C B Cui; T Mayumi; H Osada
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

5.  Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

Authors:  L A Speicher; V R Sheridan; A K Godwin; K D Tew
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

6.  Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.

Authors:  W Albrecht; H Van Poppel; S Horenblas; G Mickisch; A Horwich; V Serretta; G Casetta; J M Maréchal; W G Jones; S Kalman; R Sylvester
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.